Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817970 · ClinicalTrials.gov registry record · Phase 3
Cisplatin Disposition and Kidney Injury
A Phase 3 study of Nephrotoxicity, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
- 2
- Study locations
NCT03817970: Active Phase 3 study of Nephrotoxicity, sponsored by University of Colorado, Denver.
NCT03817970 is a Phase 3 study of Nephrotoxicity that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 72 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03817970, a Phase 3 study of Nephrotoxicity, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.
Primary Outcome
The effects of 5-HT3 antagonist antiemetic drugs on cisplatin kidney injury as indicated by a 1.5 fold increase in the urinary biomarker panel values at 3 days after treatment
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Granisetron
- DRUG Palonosetron
Study Locations (2)
Colorado
- UCHealth-Metro Denver - Denver
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
What the registry record for NCT03817970 still lists
NCT03817970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Nephrotoxicity appearing as the primary indexed condition, and to 3 interventions - of which Ondansetron is the first listed.
NCT03817970 reports a single indexed study location in Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT03817970 about?
NCT03817970 is a clinical study titled "Cisplatin Disposition and Kidney Injury". This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidn...
What is the current status of trial NCT03817970?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2019-11-15. Estimated completion is 2027-12-31.
What conditions does trial NCT03817970 study?
This clinical trial studies the following conditions: Nephrotoxicity.
What interventions are being tested in trial NCT03817970?
The interventions under investigation include: Ondansetron (DRUG), Granisetron (DRUG), Palonosetron (DRUG).
Who is sponsoring clinical trial NCT03817970?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817970 being conducted?
This trial has 2 study locations across Colorado, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nephrotoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03817970's enrollment target sits among peer trials
72 1780th of 2000 higher than 217 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI